Because ligand-bound EphA2 turns the oncogenic receptor into a tumor suppressor, the design of ephrin mimetics, hence synthetic agonistic EphA2-targeting agents, represents a potentially therapeutically-viable strategy. The gene discussed is EPHA2; the disease is neoplasm.